Ann: Appointment of Non-Executive Director, page-98

For those who thought DESTUM was a waste of time and $$


Destum Partners Acts as Transaction Advisor to Antisense Therapeutics on $110M Rare Diseases Deal

GOTEBORG, SWEDEN and TREVOSE, PA, USA and VICTORIA, AUSTRALIA, May 15, 2015 - Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics’ ATL1103 for endocrinology applications. Destum Partners acted as Antisense Therapeutics’ exclusive transaction advisor throughout the process.